Bicara Therapeutics (BCAX) Enterprise Value (2023 - 2026)

Bicara Therapeutics has reported Enterprise Value for 4 years, with the latest figure at -$539.8 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 16.8% year-over-year to -$539.8 million; the trailing twelve-month figure through Mar 2026 stood at -$539.8 million (down 16.8% YoY), and the FY2025 full-year result was -$414.8 million, up 15.3% from the prior year.
• Enterprise Value for Q1 2026 stood at -$539.8 million, down from -$414.8 million in the prior quarter.
• The five-year high for Enterprise Value was -$230.4 million in Q4 2023, with the low at -$539.8 million in Q1 2026.
• Historically, Enterprise Value has averaged -$423.0 million across 4 years, with a median of -$449.4 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value sank 112.51% — and 2025, when it surged 44.28%.
• Bicara Therapeutics' Enterprise Value stood at -$230.4 million in 2023, then tumbled by 112.51% to -$489.7 million in 2024, then rose by 15.3% to -$414.8 million in 2025, then tumbled by 30.12% to -$539.8 million in 2026.
• The last three Enterprise Value figures came in at -$539.8 million (Q1 2026), -$414.8 million (Q4 2025), and -$290.2 million (Q3 2025), per Business Quant data.